| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/ANNONC/MDT416 |
| P698 | PubMed publication ID | 24146220 |
| P2093 | author name string | W Sun | |
| P J O'Dwyer | |||
| T Uehara | |||
| N Damjanov | |||
| A Sepulveda | |||
| D P S Sohal | |||
| B J Giantonio | |||
| K Mykulowycz | |||
| M Carberry | |||
| M Jacobs-Small | |||
| P Wissel | |||
| U R Teitelbaum | |||
| P2860 | cites work | Cancer statistics, 2013 | Q27860762 |
| Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines | Q33611056 | ||
| Phase II study of erlotinib in patients with advanced biliary cancer | Q33997258 | ||
| Understanding resistance to EGFR inhibitors-impact on future treatment strategies | Q34088424 | ||
| Comparing antibody and small-molecule therapies for cancer | Q34560075 | ||
| Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer | Q34618537 | ||
| Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study | Q34623625 | ||
| Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. | Q34624122 | ||
| Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma | Q36614705 | ||
| Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma | Q37177871 | ||
| Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009 | Q37347327 | ||
| Genetics of biliary tract cancers and emerging targeted therapies | Q37765099 | ||
| Targeted therapy for biliary tract cancers | Q37982650 | ||
| Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer | Q39647813 | ||
| A phase 1 study of fixed dose rate gemcitabine and irinotecan in patients with advanced pancreatic and biliary cancer | Q40164640 | ||
| Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells | Q40497486 | ||
| Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma | Q43005729 | ||
| Cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas | Q46891324 | ||
| K-ras codon 12 and p53 mutations in biopsy specimens and bile from biliary tract cancers | Q50154592 | ||
| Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. | Q53393758 | ||
| P433 | issue | 12 | |
| P921 | main subject | cholangiocarcinoma | Q124292 |
| irinotecan | Q412197 | ||
| phase II clinical trial | Q42824440 | ||
| P304 | page(s) | 3061-3065 | |
| P577 | publication date | 2013-10-20 | |
| P1433 | published in | Annals of Oncology | Q326122 |
| P1476 | title | A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma | |
| P478 | volume | 24 |
| Q48126437 | A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer |
| Q48336081 | Adjuvant therapy is associated with improved survival after curative resection for hilar cholangiocarcinoma: A multi-institution analysis from the U.S. extrahepatic biliary malignancy consortium. |
| Q89947281 | Anti-EGFR Monoclonal Antibodies in Advanced Biliary Tract Cancer: A Systematic Review and Meta-analysis |
| Q39289707 | Biliary cancer: intrahepatic cholangiocarcinoma vs. extrahepatic cholangiocarcinoma vs. gallbladder cancers: classification and therapeutic implications |
| Q33977171 | Chemotherapy and targeted therapy for gall bladder cancer |
| Q41754639 | Comparative Analysis of Left- Versus Right-sided Resection in Klatskin Tumor Surgery: can Lesion Side be Considered a Prognostic Factor? |
| Q39453572 | Current biologics for treatment of biliary tract cancers |
| Q89848700 | EGFRvIII: An Oncogene with Ambiguous Role |
| Q41105428 | Expression and activation of EGFR and STAT3 during the multistage carcinogenesis of intrahepatic cholangiocarcinoma induced by 3'-methyl-4 dimethylaminoazobenzene in rats |
| Q53347236 | Gemcitabine, capecitabine and oxaliplatin with or without cetuximab in advanced biliary tract carcinoma. |
| Q37017110 | Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design |
| Q38703148 | Immunotherapeutic Approaches to Biliary Cancer |
| Q48327823 | Incidence, risk and prognostic role of anti-epidermal growth factor receptor-induced skin rash in biliary cancer: a meta-analysis. |
| Q36488070 | Molecular genetics and targeted therapeutics in biliary tract carcinoma |
| Q38619219 | New Horizons for Precision Medicine in Biliary Tract Cancers |
| Q54476966 | New molecular and immunotherapeutic approaches in biliary cancer. |
| Q38799963 | Novel investigational therapies for treating biliary tract carcinoma |
| Q40352514 | Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study). |
| Q50609881 | Phase I trial of S-1 every other day in combination with gemcitabine/cisplatin for inoperable biliary tract cancer. |
| Q33994406 | Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer. |
| Q48203761 | Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR. |
| Q27016150 | Progression of targeted therapy in advanced cholangiocarcinoma |
| Q92460033 | Second-line therapies in advanced biliary tract cancers |
| Q40686537 | TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer |
| Q26798443 | Targeted Therapy in Biliary Tract Cancers |
| Q30234532 | Targeted therapy in biliary tract cancers-current limitations and potentials in the future |
| Q26751224 | The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets |
| Q33621529 | Therapeutic options for intrahepatic cholangiocarcinoma |
Search more.